Healthcare Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1NEUP Neuphoria Therapeutics
1.26 K
 0.09 
 17.31 
 1.61 
2ACOG Alpha Cognition Common
445.52
(0.02)
 4.41 
(0.07)
3VSEE VSee Health,
359.54
(0.06)
 6.22 
(0.37)
4HCA HCA Holdings
293.44
(0.01)
 1.89 
(0.03)
5DVA DaVita HealthCare Partners
93.82
(0.09)
 2.18 
(0.19)
6AVR Anteris Technologies Global
91.17
 0.11 
 4.13 
 0.45 
7HURA TuHURA Biosciences
73.38
(0.15)
 7.77 
(1.19)
8AAPG AAPG
60.58
 0.24 
 3.46 
 0.81 
9LLY Eli Lilly and
55.78
 0.14 
 1.82 
 0.25 
10GH Guardant Health
55.67
 0.09 
 4.45 
 0.42 
11BSGM BioSig Technologies, Common
36.58
(0.07)
 9.74 
(0.66)
12NTRA Natera Inc
23.44
(0.02)
 2.44 
(0.05)
13IDXX IDEXX Laboratories
23.34
 0.08 
 2.07 
 0.16 
14TLX Telix Pharmaceuticals Limited
20.71
 0.10 
 3.23 
 0.33 
15MDCX Medicus Pharma Ltd
13.49
 0.13 
 6.76 
 0.90 
16WAT Waters
12.37
 0.01 
 1.65 
 0.01 
17PACS PACS Group,
11.04
(0.11)
 2.55 
(0.27)
18WGS GeneDx Holdings Corp
10.87
 0.08 
 8.16 
 0.69 
19GRDN Guardian Pharmacy Services,
9.8
(0.12)
 3.32 
(0.39)
20DWTX Dogwood Therapeutics,
8.6
 0.11 
 51.01 
 5.79 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.